Anavex Life Sciences Corp. — FY2021 Form 10-K
Reporting period: Fiscal year ended September 30, 2021 (not a standalone fourth-quarter report). Anavex is a clinical-stage biopharmaceutical company developing precision-medicine treatments for CNS diseases. It had no operating revenue and no approved commercial products.
Financial performance and position
| Metric | FY2021 / September 30, 2021 | FY2020 / September 30, 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $33.0 million | $25.2 million |
| General and administrative expense | $9.0 million | $5.9 million |
| Total operating expenses | $42.0 million | $31.1 million |
| Net loss | $37.9 million; $0.54 per share | $26.3 million; $0.45 per share |
| Operating cash used | $30.4 million | $21.3 million |
| Cash and cash equivalents | $152.1 million | $29.2 million |
| Working capital | $150.8 million | $27.2 million |
| Total liabilities | $10.8 million | $7.3 million |
Operating expenses rose 35%, primarily as clinical programs advanced; net loss widened by $11.6 million. Research and development incentive income was $4.5 million, largely from the Australian tax incentive program. The filing reports no debt balance; liabilities presented are current accounts payable, accruals and deferred grant income. Profit margins are not meaningful given the absence of revenue.
Financing provided $153.2 million net cash in FY2021, including $76.7 million net proceeds from at-the-market sales and $46.9 million from a registered direct offering. Shares outstanding increased from 62.0 million to 75.9 million during the year. Management said existing working capital should fund requirements beyond 12 months after issuance of the statements, while noting continued negative cash flows and possible need for additional financing.
Business and clinical developments
- ANAVEX 2-73: Alzheimer’s Phase 2b/3 study completed enrollment of 509 patients in June 2021; results were pending. A long-term open-label extension is underway.
- Rett syndrome: The U.S. Phase 2 study completed in December 2020. The company reported positive, statistically significant secondary endpoint results, including RSBQ and CGI-I measures. The AVATAR Phase 2 and EXCELLENCE Phase 2/3 pediatric studies continued; AVATAR topline data was expected around year-end 2021.
- Parkinson’s disease dementia: The company reported completion of a 132-patient Phase 2 trial, with safety and efficacy findings it characterized as positive. Further trials were subject to FDA guidance.
- ANAVEX 3-71: A first-in-human Phase 1 trial for healthy volunteers was underway. Other compounds were in preclinical development.
The reported clinical findings are company-reported; the filing does not establish regulatory approval or confirm that benefits will be reproduced in later trials. Management expects R&D spending to increase as studies and staffing expand. No specific revenue or profitability guidance was provided.
Risks, contingencies and other items
- The company has accumulated losses of approximately $197.6 million and has never generated operating revenue; it expects negative cash flows for the foreseeable future. Continued development depends on trial outcomes and access to capital.
- Clinical efficacy, safety, enrollment, timelines, manufacturing, regulatory approval and commercialization are uncertain. Fast Track, orphan-drug and other designations do not assure approval or faster review.
- Potential dilution is material: the company raised equity during FY2021, had 200 million authorized common shares, and disclosed outstanding options and warrants.
- COVID-19 had no material reported FY2021 financial impact, but management said future effects on trials and operations remained uncertain.
- The Australian Tax Office was reviewing the company’s FY2020 R&D incentive return; the company said it did not expect an adverse finding. Ordinary-course claims and proceedings were disclosed, with no material pending litigation identified.
- Auditor BDO issued unqualified opinions on the financial statements and internal controls; no critical audit matters were identified.
Investor verification priorities
- Check subsequent Alzheimer’s, Rett syndrome and Parkinson’s trial results, regulatory feedback, and whether findings are supported by full data and peer review.
- Reconcile cash runway and planned trial spending against financing needs, potential equity issuance and dilution.
- Track collection and audit outcomes for Australian R&D credits and the related receivable balance.
- Review clinical-trial timelines, enrollment, safety disclosures, and any changes to management’s stated outlook.